1
|
Kim T, Martínez-Bonet M, Wang Q, Hackert N, Sparks JA, Baglaenko Y, Koh B, Darbousset R, Laza-Briviesca R, Chen X, Aguiar VRC, Chiu DJ, Westra HJ, Gutierrez-Arcelus M, Weirauch MT, Raychaudhuri S, Rao DA, Nigrovic PA. Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development. Nat Commun 2024; 15:2150. [PMID: 38459032 PMCID: PMC10923805 DOI: 10.1038/s41467-024-46457-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 02/26/2024] [Indexed: 03/10/2024] Open
Abstract
Fine-mapping and functional studies implicate rs117701653, a non-coding single nucleotide polymorphism in the CD28/CTLA4/ICOS locus, as a risk variant for rheumatoid arthritis and type 1 diabetes. Here, using DNA pulldown, mass spectrometry, genome editing and eQTL analysis, we establish that the disease-associated risk allele is functional, reducing affinity for the inhibitory chromosomal regulator SMCHD1 to enhance expression of inducible T-cell costimulator (ICOS) in memory CD4+ T cells from healthy donors. Higher ICOS expression is paralleled by an increase in circulating T peripheral helper (Tph) cells and, in rheumatoid arthritis patients, of blood and joint fluid Tph cells as well as circulating plasmablasts. Correspondingly, ICOS ligation and carriage of the rs117701653 risk allele accelerate T cell differentiation into CXCR5-PD-1high Tph cells producing IL-21 and CXCL13. Thus, mechanistic dissection of a functional non-coding variant in human autoimmunity discloses a previously undefined pathway through which ICOS regulates Tph development and abundance.
Collapse
Affiliation(s)
- Taehyeung Kim
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Marta Martínez-Bonet
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Laboratory of Immune-regulation, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - Qiang Wang
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Nicolaj Hackert
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Division of Rheumatology, Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- Institute for Immunology, Heidelberg University Hospital, Heidelberg, Germany
| | - Jeffrey A Sparks
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Yuriy Baglaenko
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Byunghee Koh
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Roxane Darbousset
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Raquel Laza-Briviesca
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Xiaoting Chen
- Center for Autoimmune Genomics and Etiology, Cincinnati Children's Medical Center, Cincinnati, OH, USA
| | - Vitor R C Aguiar
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Darren J Chiu
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Harm-Jan Westra
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Genetics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, The Netherlands
| | - Maria Gutierrez-Arcelus
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Matthew T Weirauch
- Center for Autoimmune Genomics and Etiology, Cincinnati Children's Medical Center, Cincinnati, OH, USA
- Divisions of Human Genetics, Biomedical Informatics, and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Soumya Raychaudhuri
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Deepak A Rao
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Peter A Nigrovic
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
2
|
Huang Z, You X, Chen L, Du Y, Brodeur K, Jee H, Wang Q, Linder G, Darbousset R, Cunin P, Chang MH, Wactor A, Wauford BM, Todd MJC, Wei K, Li Y, Levescot A, Iwakura Y, Pascual V, Baldwin NE, Quartier P, Li T, Gianatasio MT, Hasserjian RP, Henderson LA, Sykes DB, Mellins ED, Canna SW, Charles JF, Nigrovic PA, Lee PY. mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome. Nat Commun 2022; 13:6915. [PMID: 36443301 PMCID: PMC9705324 DOI: 10.1038/s41467-022-34480-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 10/26/2022] [Indexed: 11/29/2022] Open
Abstract
Still's disease is a severe inflammatory syndrome characterized by fever, skin rash and arthritis affecting children and adults. Patients with Still's disease may also develop macrophage activation syndrome, a potentially fatal complication of immune dysregulation resulting in cytokine storm. Here we show that mTORC1 (mechanistic target of rapamycin complex 1) underpins the pathology of Still's disease and macrophage activation syndrome. Single-cell RNA sequencing in a murine model of Still's disease shows preferential activation of mTORC1 in monocytes; both mTOR inhibition and monocyte depletion attenuate disease severity. Transcriptomic data from patients with Still's disease suggest decreased expression of the mTORC1 inhibitors TSC1/TSC2 and an mTORC1 gene signature that strongly correlates with disease activity and treatment response. Unrestricted activation of mTORC1 by Tsc2 deletion in mice is sufficient to trigger a Still's disease-like syndrome, including both inflammatory arthritis and macrophage activation syndrome with hemophagocytosis, a cellular manifestation that is reproduced in human monocytes by CRISPR/Cas-mediated deletion of TSC2. Consistent with this observation, hemophagocytic histiocytes from patients with macrophage activation syndrome display prominent mTORC1 activity. Our study suggests a mechanistic link of mTORC1 to inflammation that connects the pathogenesis of Still's disease and macrophage activation syndrome.
Collapse
Affiliation(s)
- Zhengping Huang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA ,grid.413405.70000 0004 1808 0686Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China
| | - Xiaomeng You
- grid.38142.3c000000041936754XDepartment of Orthopaedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Liang Chen
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Yan Du
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.412465.0Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Kailey Brodeur
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Hyuk Jee
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Qiang Wang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Grace Linder
- grid.239552.a0000 0001 0680 8770Blood Bank and Transfusion Medicine Division, Children’s Hospital of Philadelphia, Philadelphia, PA USA
| | - Roxane Darbousset
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Pierre Cunin
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Margaret H. Chang
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Alexandra Wactor
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Brian M. Wauford
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Marc J. C. Todd
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - Kevin Wei
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Ying Li
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Anais Levescot
- grid.462336.6Université Paris Cité, Institut Imagine, INSERM UMR1163, Laboratory Intestinal Immunity, Paris, France
| | - Yoichiro Iwakura
- grid.143643.70000 0001 0660 6861Centre for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan
| | - Virginia Pascual
- grid.5386.8000000041936877XDepartment of Pediatrics and Drukier Institute for Children’s Health, Weill Cornell Medicine, New York, NY USA
| | - Nicole E. Baldwin
- grid.486749.00000 0004 4685 2620Baylor Scott & White Research Institute, Dallas, TX USA
| | - Pierre Quartier
- grid.5842.b0000 0001 2171 2558Pediatric Immunology, Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris, Universite de Paris, Paris, France
| | - Tianwang Li
- grid.413405.70000 0004 1808 0686Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China
| | - Maria T. Gianatasio
- grid.416636.00000 0004 0460 4960Mass General Brigham Healthcare Center - Salem Hospital, Salem, MA USA
| | - Robert P. Hasserjian
- grid.38142.3c000000041936754XDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
| | - Lauren A. Henderson
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| | - David B. Sykes
- grid.32224.350000 0004 0386 9924Center for Regenerative Medicine, Massachusetts General Hospital, Boston, USA
| | - Elizabeth D. Mellins
- grid.168010.e0000000419368956Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA USA
| | - Scott W. Canna
- grid.239552.a0000 0001 0680 8770Division of Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, PA USA
| | - Julia F. Charles
- grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDepartment of Orthopaedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Peter A. Nigrovic
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA ,grid.38142.3c000000041936754XDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
| | - Pui Y. Lee
- grid.38142.3c000000041936754XDivision of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA
| |
Collapse
|
3
|
Crescence L, Darbousset R, Caroff E, Hubler F, Riederer MA, Panicot-Dubois L, Dubois C. Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model. Thromb Res 2021; 200:133-140. [PMID: 33610885 DOI: 10.1016/j.thromres.2021.01.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 01/11/2021] [Accepted: 01/28/2021] [Indexed: 01/04/2023]
Abstract
INTRODUCTION Selatogrel is a reversible antagonist of the P2Y12 receptor. In rat thrombosis/haemostasis models, selatogrel was associated with lower blood loss than clopidogrel or ticagrelor at equivalent anti-thrombotic effect. MATERIAL AND METHODS We sought to elucidate the mechanism underlying the observed differences in blood loss, using real-time intravital microscopy in mouse. RESULTS Selatogrel, ticagrelor and clopidogrel dose-dependently inhibited laser-induced platelet thrombus formation. At maximal antithrombotic effect, only small mural platelets aggregates, corresponding to hemostatic seals, were present. The phenotype of these hemostatic seals was dependent on the type of P2Y12 receptor antagonist. In the presence of clopidogrel and ticagrelor, detachment of platelets from the hemostatic seals was increased, indicative of reduced stability. In contrast, in the presence of selatogrel, platelet detachment was not increased. Moreover, equivalent antithrombotic dosing regimens of ticagrelor and clopidogrel reduced laser-induced calcium mobilization in the endothelium, restricted neutrophil adhesion and subsequent fibrin formation and thus reduced fibrin-mediated stabilization of the hemostatic seals. The effects of ticagrelor were also observed in P2Y12 receptor deficient mice, indicating that the effects are off-target and independent of the P2Y12 receptor. In contrast, selatogrel did not interfere with these elements of haemostasis in wild-type or in P2Y12 receptor deficient mice. CONCLUSION In the presence of selatogrel the stability of hemostatic seals was unperturbed, translating to an improved blood loss profile. Our data suggest that the mechanism underlying the differences in blood loss profiles of P2Y12 receptor antagonists is by off-target interference with endothelial activation, neutrophil function and thus, fibrin-mediated stabilization of haemostatic seals.
Collapse
Affiliation(s)
- Lydie Crescence
- Aix Marseille Université, INSERM 1263, INRAE 1260 27 Boulevard Jean Moulin, Marseille, France
| | - Roxane Darbousset
- Aix Marseille Université, INSERM 1263, INRAE 1260 27 Boulevard Jean Moulin, Marseille, France
| | - Eva Caroff
- Idorsia Pharmaceuticals Ltd. DD Chemistry, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Francis Hubler
- Idorsia Pharmaceuticals Ltd. DD Chemistry, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Markus A Riederer
- Idorsia Pharmaceuticals Ltd. DD Biology, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.
| | - Laurence Panicot-Dubois
- Aix Marseille Université, INSERM 1263, INRAE 1260 27 Boulevard Jean Moulin, Marseille, France
| | - Christophe Dubois
- Aix Marseille Université, INSERM 1263, INRAE 1260 27 Boulevard Jean Moulin, Marseille, France
| |
Collapse
|
4
|
Makhloufi C, Crescence L, Darbousset R, McKay N, Massy ZA, Dubois C, Panicot-Dubois L, Burtey S, Poitevin S. Assessment of Thrombotic and Bleeding Tendency in Two Mouse Models of Chronic Kidney Disease: Adenine-Diet and 5/6th Nephrectomy. TH Open 2020; 4:e66-e76. [PMID: 32309772 PMCID: PMC7162676 DOI: 10.1055/s-0040-1705138] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 01/27/2020] [Indexed: 12/15/2022] Open
Abstract
The coexistence of bleeding and thrombosis in patients with chronic kidney disease (CKD) is frequent and poorly understood. Mouse models are essential to understand complications of CKD and to develop new therapeutic approaches improving the health of patients. We evaluated the hemostasis in two models of renal insufficiency: adenine-diet and 5/6th nephrectomy (5/6Nx). Compared with 5/6Nx mice, mice fed with 0.25% adenine had more severe renal insufficiency and so higher levels of prothrombotic uremic toxins like indoxyl sulfate. More severe renal inflammation and fibrosis were observed in the adenine group, as demonstrated by histological and reverse transcription quantitative polymerase chain reaction experiments. Liver fibrinogen γ chain expression and level of plasma fibrinogen were increased only in adenine mice. In both CKD mouse models, tissue factor (TF) expression was increased in kidney and aorta extracts. Immunochemistry analysis of kidney sections showed that TF is localized in the vascular walls. Thrombin–antithrombin complexes were significantly increased in plasma from both adenine and 5/6Nx mice. Tail bleeding time increased significantly only in adenine mice, whereas platelet count was not significant altered. Finally, results obtained by intravital microscopy after laser-induced endothelial injury showed impaired platelet function in adenine mice and an increase in fibrin generation in 5/6Nx mice. To summarize, adenine diet causes a more severe renal insufficiency compared with 5/6Nx. The TF upregulation and the hypercoagulable state were observed in both CKD models. Bleeding tendency was observed only in the adenine model of CKD that recapitulates the whole spectrum of hemostasis abnormalities observed in advanced human CKD.
Collapse
Affiliation(s)
| | - Lydie Crescence
- Aix Marseille Univ, INSERM 1263, INRAE, C2VN, Marseille, France
| | - Roxane Darbousset
- Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
| | - Nathalie McKay
- Aix Marseille Univ, INSERM 1263, INRAE, C2VN, Marseille, France
| | - Ziad A Massy
- Centre for Research in Epidemiology and Population Health (CESP), University Paris-Saclay, Villejuif, France.,Department of Nephrology, Ambroise Paré University Hospital, Boulogne Billancourt/Paris, France
| | | | | | - Stéphane Burtey
- Aix Marseille Univ, INSERM 1263, INRAE, C2VN, Marseille, France.,Centre de Néphrologie et Transplantation Rénale, APHM, Marseille, France
| | | |
Collapse
|
5
|
Schoenwaelder SM, Darbousset R, Cranmer SL, Ramshaw HS, Orive SL, Sturgeon S, Yuan Y, Yao Y, Krycer JR, Woodcock J, Maclean J, Pitson S, Zheng Z, Henstridge DC, van der Wal D, Gardiner EE, Berndt MC, Andrews RK, James DE, Lopez AF, Jackson SP. Correction: Corrigendum: 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function. Nat Commun 2017; 8:16125. [PMID: 28853434 PMCID: PMC5582346 DOI: 10.1038/ncomms16125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
6
|
Hubert L, Darbousset R, Panicot-Dubois L, Robert S, Sabatier F, Fallague K, Dignat-George F, Dubois C. Neutrophils recruit and activate human endothelial colony-forming cells at the site of vessel injury via P-selectin glycoprotein ligand-1 and L-selectin. J Thromb Haemost 2014; 12:1170-81. [PMID: 24606340 DOI: 10.1111/jth.12551] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Accepted: 02/12/2014] [Indexed: 12/14/2022]
Abstract
BACKGROUND Endothelial colony-forming cells (ECFCs) represent a subpopulation of circulating endothelial progenitor cells that have been implicated in vascular repair. However, no study has evaluated the role of ECFCs in endothelial injury leading to thrombus formation. OBJECTIVE We investigated the kinetics, mechanisms and role of ECFC recruitment in the dynamics of thrombus formation and stabilization. METHODS AND RESULTS Using digital intravital microscopy in living mice, we show that ECFCs, but not mature endothelial cells, adhere to sites of laser-induced injury and do not affect the kinetics of thrombus formation. This interaction occurs once the platelet thrombus has been stabilized, and is dependent on the presence of neutrophils but not platelets or fibrin. In vitro, the interaction of the activated neutrophils with activated endothelial cells is a prerequisite for the capture of ECFCs. Neutrophils activate ECFCs and increase their angiogenic properties, such as their ability to migrate and to form pseudocapillaries. This newly identified interaction of ECFCs with the neutrophils is mediated by the P-selectin glycoprotein ligand-1 (PSGL-1)/L-selectin axis both in vitro and in vivo. CONCLUSIONS This study is the first demonstration that neutrophils present at the site of injury recruit ECFCs via PSGL-1/L-selectin. This interaction between neutrophils and ECFCs could play a key role in the regeneration of injured vessels in pathophysiologic conditions.
Collapse
Affiliation(s)
- L Hubert
- Aix Marseille Université, VRCM INSERM UMR-S1076, Marseille, France
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer 2014; 136:462-75. [PMID: 24889539 DOI: 10.1002/ijc.28997] [Citation(s) in RCA: 102] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 05/12/2014] [Accepted: 05/20/2014] [Indexed: 12/16/2022]
Abstract
Venous thromboembolism constitutes one of the main causes of death during the progression of a cancer. We previously demonstrated that tissue factor (TF)-bearing cancer cell-derived microparticles accumulate at the site of injury in mice developing a pancreatic cancer. The presence of these microparticles at the site of thrombosis correlates with the size of the platelet-rich thrombus. The objective of this study was to determine the involvement of TF expressed by cancer cell-derived microparticles on thrombosis associated with cancer. We observed that pancreatic cancer cell derived microparticles expressed TF, its inhibitor tissue factor pathway inhibitor (TFPI) as well as the integrins αvβ1 and αvβ3. In mice bearing a tumor under-expressing TF, a significant decrease in circulating TF activity associated with an increase bleeding time and a 100-fold diminished fibrin generation and platelet accumulation at the site of injury were observed. This was mainly due to the interaction of circulating cancer cell-derived microparticles expressing TFPI with activated platelets and fibrinogen. In an ectopic model of cancer, treatment of mice with Clopidogrel, an anti-platelet drug, decreased the size of the tumors and restored hemostasis by preventing the accumulation of cancer cell-derived microparticles at the site of thrombosis. In a syngeneic orthotopic model of pancreatic cancer Clopidogrel also significantly inhibited the development of metastases. Together, these results indicate that an anti-platelet strategy may efficiently treat thrombosis associated with cancer and reduce the progression of pancreatic cancer in mice.
Collapse
Affiliation(s)
- Soraya Mezouar
- Aix Marseille Université, INSERM UMR-S1076, 13385, Marseille, France
| | | | | | | | | |
Collapse
|
8
|
Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of Platelet-Derived Microparticles in Tumor Progression and Thrombosis. Semin Oncol 2014; 41:346-58. [DOI: 10.1053/j.seminoncol.2014.04.010] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
9
|
Poesen R, Viaene L, Bammens B, Claes K, Evenepoel P, Meijers B, Bozic M, De Pablo C, Alvarez A, Sanchez-Nino MD, Ortiz A, Fernandez E, Valdivielso JM, Speer T, Zewinger S, Holy EW, Stahli BE, Triem S, Cvija H, Rohrer L, Seiler S, Heine GH, Jankowski V, Jankowski J, Camici G, Akhmedov A, Luscher TF, Tanner FC, Fliser D, Isoyama N, Leurs P, Qureshi AR, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B, Bolasco P, Palleschi S, Rossi B, Atti M, Amore A, Coppo R, Loiacono E, Ghezzi PM, Palladino G, Caiazzo M, Di Napoli A, Tazza L, Franco F, Chicca S, Bossola M, Di Lallo D, Michelozzi P, Davoli M, Lucisano S, Arena A, Lupica R, Cernaro V, Trimboli D, Aloisi C, Montalto G, Santoro D, Buemi M, Burtey S, Poitevin S, Darbousset R, Gondouin B, Dubois C, Erkmen Uyar M, Bal Z, Bayraktar N, Gurlek Demirci B, Sayin B, Sezer S, Rogacev K, Zawada A, Emrich I, Seiler S, Bohm M, Fliser D, Woollard K, Heine G, Gbandjaba NY, Ghalim N, Saile R, Khalil A, Fujii H, Yamashita Y, Yonekura Y, Nakai K, Kono K, Goto S, Sugano M, Goto S, Ito Y, Nishi S, Leurs P, Meuwese C, Carrero JJ, Qureshi AR, Anderstam B, Barany P, Heimburger O, Stenvinkel P, Lindholm B, Riccio E, Sabbatini M, Bellizzi V, Pisani A, Svedberg O, Stenvinkel P, Qureshi AR, Barany P, Heimburger O, Leurs P, Isoyama N, Lindholm B, Anderstam B, Barreto-Silva MI, Lemos C, Costa-Silva F, Mendes R, Bregman R, Barreto - Silva MI, Lemos C, Vargas S, Barja-Fidalgo TC, Bregman R, Sidoti A, Lusini ML, Biagioli M, Sereni L, Ghezzi PM, Caiazzo M, Palladino G, Kara E, Ahbap E, Basturk T, Koc Y, Sakaci T, Sahutoglu T, Sevinc M, Akgol C, Unsal A, Snaedal S, Qureshi AR, Carrero JJ, Heimburger O, Stenvinkel P, Barany P, Paliouras C, Haviatsos T, Lamprianou F, Papagiannis N, Ntetskas G, Roufas K, Karvouniaris N, Anastasakis E, Moschos N, Alivanis P, Santoro D, Ingegneri MT, Vita G, Pisacane A, Bellinghieri G, Savica V, Buemi M, Lucisano S, Kim HK, Kim SC, Kim MG, Jo SK, Cho WY, Altunoglu A, Yavuz D, Canoz MB, Yavuz R, Karakas LA, Bayraktar N, Colak T, Sezer S, Ozdemir FN, Haberal M, Akbasli AC, Keven K, Erbay B, Nebio lu S, Loboda O, Dudar I, Krot V, Alekseeva V, Grabulosa CC, De Carvalho JTG, Manfredi SR, Canziani ME, Quinto BMR, Peres AT, Batista MC, Cendoroglo M, Dalboni MA, Zingerman B, Azoulay O, Gamzo Z, Rozen-Zvi B, Stefan G, Capusa C, Stancu S, Ilyes A, Viasu L, Mircescu G, Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, Eyileten T, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M, Kim YN, Park K, Gwoo S, Shin HS, Jung YS, Rim H, Rhew HY, Gok M, Kurt Y, Unal HU, CetInkaya H, Karaman M, EyIeten T, Vural A, Yilmaz MI, Oguz Y, Flisi Ski M, Brymora A, StrozEcki P, Stefa Ska A, Manitius J, Donderski R, Mi Kowiec-Wi Niewska I, Kretowicz M, Johnson R, Kami Ska A, Junik R, Siodmiak J, Stefa Ska A, Odrowaz-Sypniewska G, Manitius J, Tasic D, Radenkovic S, Kocic G, Wyskida K, Spiechowicz-Zato U, Rotkegel S, Ciepal J, Klein D, Bozentowicz-Wikarek M, Brzozowska A, Olszanecka-Glinianowicz M, Chudek J, Dimitrijevic Z, Cvetkovic T, Mitic B, Paunovic K, Paunovic G, Stojanovic M, Velickovic-Radovanovic R, Gliga ML, Gliga PM, Stoica C, Tarta D, Dogaru G. CKD NUTRITION, INFLAMMATION AND OXIDATIVE STRESS. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Darbousset R, Mezouar S, Bonier R, Sbarra V, Farge-Bancel D, Frère C, Dubois C, Panicot-Dubois L. On the use of anti-platelet drugs to diminish both tumor growth and thrombosis. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70048-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Mezouar S, Darbousset R, Germain S, Frère C, Panicot-Dubois L, Dubois C. Involvement of tissue factor expressed by cancer cells on tumor growth and thrombosis associated with cancer. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70072-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|